ライフサイエンスコーパス: labetalol

1 The most common initial drug was labetalol (48%), followed by nicardipine (15%), hydralaz

2 adrenergic receptor blockers (phentolamine, labetalol), a calcium channel blocker (nifedipine), and

3 Labetalol, a combined alpha1, beta1, and beta2 adrenocep

4 surements were repeated 10 and 30 mins after labetalol administration.

5 wering of blood pressure with lisinopril and labetalol after acute stroke seems to be a promising app

6 Labetalol and lisinopril are effective antihypertensive

7 4%] women vs 228 [77%] women; p=0.05) or the labetalol and methyldopa groups (p=0.80).

8 phase, the separation of the beta-blockers, labetalol and sotalol, and the binaphthyl derivatives, 1

9 ne, 295 (33%) women were assigned to receive labetalol, and 301 (33%) women were assigned to receive

10 Prior administration of phentolamine, labetalol, and nitroglycerine prevented the phenylephrin

11 re treated with phenylephrine, phentolamine, labetalol, and nitroglycerine.

12 he mixed alpha-/beta-adrenoceptor antagonist labetalol, and the alpha1-adrenoceptor antagonist prazos

13 f mixed adrenoceptor blockers carvedilol and labetalol, and the atypical antipsychotic clozapine, in

14 e outcomes were found between flecainide and labetalol antiarrhythmic effects in vitro and the clinic

15 three oral drugs-methyldopa, nifedipine, and labetalol-are viable initial options for treating severe

16 a mediator, while no significant removal of labetalol can be achieved in the absence of ABTS.

17 Our experiments indicate that labetalol can be effectively transformed by laccase-cata

18 he widespread occurrence of the beta-blocker labetalol causes environmental health concern.

19 This indicates that labetalol enhances GABAergic synaptic transmission by a

20 clude nitroprusside, diazoxide, hydralazine, labetalol, esmolol, nicardipine, nifedipine, enalaprilat

21 ted during the study: one (<1%) woman in the labetalol group had an intrapartum seizure and six (1%)

22 the nifedipine group, ten (3%) women in the labetalol group, and 11 (4%) women in the methyldopa gro

23 e nifedipine group, two [1%] neonates in the labetalol group, and three [1%] neonates in the methyldo

24 me did not differ between the nifedipine and labetalol groups (249 [84%] women vs 228 [77%] women; p=

25 o receive 10 mg oral nifedipine, 200 mg oral labetalol (hourly, in both of which the dose could be es

26 splenic, and pulmonary blood pools, whereas labetalol increased only the pulmonary blood pool.

27 Based on these data, we postulate that labetalol-induced analgesia is at least in part ascribed

28 In the presence of metoprolol, labetalol-induced increase in sIPSC frequency was signif

29 These data indicate that labetalol-induced inhibition of PAG cell firing is attri

30 ternet central randomisation to receive oral labetalol, lisinopril, or placebo if they were non-dysph

31 the efficacy and safety of three oral drugs, labetalol, nifedipine retard, and methyldopa for the man

32 anted cell entry in liver sinusoids, whereas labetalol, nifedipine, CGRP, and glucagon were ineffecti

33 frequency of primary outcome attainment than labetalol or methyldopa use.

34 al timolol and infusion of propranolol, oral labetalol, oxprenolol, propranolol, and metoprolol exhib

35 mental information for laccase-ABTS mediated labetalol reactions and the effect of graphene, which co

36 Administration of labetalol resulted in a decrease in MAP (mm Hg+/-SEM) in

37 Using patch clamp techniques, we found that labetalol reversibly increases the frequency of sIPSCs w

38 We further showed that labetalol reversibly reduced the firing rate of PAG neur

39 These results suggest that labetalol shares the same pathway as metoprolol in enhan

40 o if they were non-dysphagic, or intravenous labetalol, sublingual lisinopril, or placebo if they had

41 Intravenous labetalol was administered 90 mins after administration

42 rately inhibiting skin vasoconstriction, and labetalol was ineffective.

43 Dobutamine and labetalol were titrated to vary VO2 (range 204 to 584 mL

44 which has a much greater reactivity towards labetalol when graphene is present.

45 Furthermore, Labetalol, which is marketed for hypertension as a nonse